eso-t01
Cell therapyexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Nov 30, 2024 (NCT06691685)
Timeline
2020s
- Jan 1, 2024
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- BCMAImmunity, passive
BCMA immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06791681 | Early Phase 1 (Phase 1) | Jan 27, 2025 | Huazhong University of Science and Technology, Shenzhen Pregene Biopharma Co., Ltd. |
| NCT06691685 | Early Phase 1 (Phase 1) | Nov 30, 2024 | Huazhong University of Science and Technology, Shenzhen Pregene Biopharma Co., Ltd. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Huazhong University of Science and Technology | Academic/Hospital | 2 | 2 | 1 | 2024 |
| Shenzhen Pregene Biopharma Co., Ltd. | For profit | 2 | 0 | 1 | 2024 |
2 organizations
Page 1 / 1